伏立诺他对肺腺癌厄洛替尼耐药细胞株耐药性的影响被引量：1

The effects of vorinostat on erlotinib-resistance of lung adenocarcinoma cells

下载PDF

导出

摘要目的探讨组蛋白去乙酰化酶抑制剂伏立诺他(SAHA)对肺腺癌厄洛替尼(Erlotinib)耐药细胞株PC-9/ER耐药性的影响。方法 PC-9/ER经过厄洛替尼单药、SAHA单药、厄洛替尼联合SAHA处理48 h后,MTT法检测各种药物对PC-9/ER细胞的增殖抑制率;流式细胞术检测细胞凋亡率。结果 SAHA单药对PC-9/ER具有抑制作用,呈明显的剂量依赖效应关系。无细胞毒剂量的SAHA(1μmol/L)能明显提高PC-9/ER对厄洛替尼的敏感性。结论 SAHA能够部分改善PC-9/ER对厄洛替尼的敏感性。 Objective To investigate the impact of vorinostat （SAHA） on the erlotinib-resistance of human lung ad- enocarciuoma cell line PC-9/ER. Methods PC-9/ER cells were treated with erlotinib and SAHA, alone or in combination. The effects of proliferation inhibition were assayed by MTT method, the apoptosis ratios of cells were analyzed by flow cytometry. Results The results showed that SAHA inhibited the proliferation of PC-9/ER cells in a dose-dependent manner alone. The non-toxic doses of SAHA （ 1 μmol/L） signifi PC-9/ER to Erlotinib, and induce apoptosis. Conclusion SAHA could partially erlotinib. candy improved the sensitivity of improve PC-9/ER sensitivity to

作者吴鹏飞郝吉庆

机构地区安徽医科大学第一附属医院肿瘤内科

出处《安徽医科大学学报》 CAS 北大核心 2017年第10期1500-1503,共4页 Acta Universitatis Medicinalis Anhui

基金安徽省对外科技合作计划项目(编号:1503062023)

关键词肺腺癌组蛋白去乙酰化酶抑制剂伏立诺他厄洛替尼耐药性 lung adenocarcinoma histone deacetylase inhibitor vorinostat erlotinib drug resistance

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1梁宾勇,熊敏,纪桂宝,张二雷,张尊义,董可帅,陈孝平,黄志勇.Synergistic Suppressive Effect of PARP-1 Inhibitor PJ34 and HDAC Inhibitor SAHA on Proliferation of Liver Cancer Cells[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2015,35(4):535-540. 被引量：4
2刘慧慧,王孟昭,胡克,徐燕,马满姣,钟巍,赵静,李龙芸,王华竹.EGFR-TKI在非小细胞肺癌中耐药机制的研究进展[J].中国肺癌杂志,2013,16(10):535-540. 被引量：37

二级参考文献45

1Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res, 2006, 12(24): 7232-7241.
2Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007- 7(3): 169-181.
3Pao W, Miller VA. Epidermal growth factor receptor mutations, small- molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.J Clin Oncol, 2005, 23(11): 2556-2568.
4Schleger C, Heck R, Steinberg P. The role of wild-type and mutated N-ras in the malignant transformation of liver cells. Mol Carcinog, 2000j 28(1): 31-41.
5Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncolj 2005, 23(25): 5900-5909.
6Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005, 2(1): el7.
7Pratilas CA- Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res, 2008, 68(22): 9375-9383.
8Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curt Opin Pharmacol, 2008, 8 (4): 413-418.
9Zhu CQ.- Santos GD, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol, 2008, 26(26): 4268-4275.
10Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet, 2005, 37(12): 1315-1316.